BMS's $75mm ion channel collaboration with ICAgen
Bristol-Myers Squibb and ICAgen (ion channel drugs) will jointly discover and develop small molecule cardiovascular drugs through ion channel modulation, in a two-year agreement, with an option for a third year, worth a potential $75mm to ICAgen.
- Includes Contract
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com